checkAd
    Arcturus Therapeutics Holdings Aktie
    42,60
     
    USD
    -4,03 %
    -1,79 USD
    Letzter Kurs 22:00:00 Nasdaq
    42,53
     
    USD
    600 STK
    Geldkurs 22:02:00
    42,61
     
    USD
    1.100 STK
    Briefkurs 22:02:00
    ISIN: US03969T1097 · WKN: A2PMAS · SYM: ARCT · USA

    Neueste Nachrichten

    Arcturus Therapeutics Announces Positive Development for Cystic Fibrosis Program
    28.05.24 · Business Wire (engl.) · Arcturus Therapeutics Holdings
    Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics’ COVID-19 Vaccine
    20.05.24 · Business Wire (engl.) · Arcturus Therapeutics Holdings
    Arcturus Therapeutics to Attend Upcoming Investor & Scientific Conferences
    15.05.24 · Business Wire (engl.) · Arcturus Therapeutics Holdings
    Arcturus Therapeutics Announces First Quarter 2024 Financial Update and Pipeline Progress
    08.05.24 · Business Wire (engl.) · Arcturus Therapeutics Holdings
    Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 8, 2024
    25.04.24 · Business Wire (engl.) · Arcturus Therapeutics Holdings
    Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress
    07.03.24 · Business Wire (engl.) · Arcturus Therapeutics Holdings
    Arcturus Therapeutics to Present at the Barclays 26th Annual Global Healthcare Conference
    26.02.24 · Business Wire (engl.) · Arcturus Therapeutics Holdings
    Arcturus Therapeutics Receives Orphan Medicinal Product Designation from the European Commission (EC), for ARCT-032, for the Treatment of Cystic Fibrosis
    22.02.24 · Business Wire (engl.) · Arcturus Therapeutics Holdings
    Arcturus Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on March 7, 2024
    20.02.24 · Business Wire (engl.) · Arcturus Therapeutics Holdings
    New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster
    05.02.24 · Business Wire (engl.) · Arcturus Therapeutics Holdings
    CSL and Arcturus Therapeutics’ ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster
    21.12.23 · Business Wire (engl.) · Arcturus Therapeutics Holdings
    Arcturus Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
    04.12.23 · Business Wire (engl.) · Arcturus Therapeutics Holdings